Welsh Research Finds Mesothelioma Survival May Be Impacted by Subtle Differences in Cells, According to Surviving Mesothelioma

Share Article

A patient's mesothelioma subtype may not be the most accurate way to determine prognosis. A study in Wales say pathologists need to go further.

Phenotypes and Mesothelioma Survival

Mesothelioma Subtypes and Survival

Myxoid variant malignant pleural epithelioid mesothelioma was observed to have a favourable overall survival...

A new study on the impact of microscopic differences in mesothelioma cells suggests that these differences have a bearing on survival and should be included in pathology reports. Surviving Mesothelioma has just posted an article on the new research. Click here to read it now.

Scientists at the University Hospital of Wales in Cardiff analyzed nearly 200 cases of malignant pleural mesothelioma and found that patients with a very specific variant had better survival odds than others with the same subtype.

“Myxoid variant malignant pleural epithelioid mesothelioma was observed to have a favourable overall survival compared with pleomorphic form,” writes author Fouad Sami Alchami, MD.

The research, published in the Journal of Clinical Pathology, suggests that mesothelioma phenotypes, variations within the three major subtypes, ought to be shared with doctors and patients.

“The suggestion is that knowing a mesothelioma patient’s phenotype could lead to a more accurate prognosis and could better equip both patients and their doctors to understand and chart their mesothelioma treatment path,” says Alex Strauss, Managing Editor of Surviving Mesothelioma.

To read the details of the new study, as well as a breakdown of the three major mesothelioma subtypes and epithelioid phenotypes, see Mesothelioma Survival May Hinge on Microscopic Cell Differences, now available on the Surviving Mesothelioma website.

Alchami, FS, et al, “Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma,” October 18, 2016, Journal of Clinical Pathology, http://jcp.bmj.com/content/early/2016/10/18/jclinpath-2016-203993.abstract

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Ellis
Cancer Monthy
+1 (919) 570-8595
Email >
Follow us on
Visit website